Natural potent antienterovirus D68 (anti-EV-D68) agent

Cancer chemoprevebtive agent

Novel antistaphyloccocal agent, attenuating inhibition of hERG potassium channel current

Novel angiotensin-(1-7) Mas receptor agonist

Novel non-peptide Ang-(1-7) mimetic, inhibiting perivascular inflammation, through the reduction of chemokine expression in pVAT, as well as through direct actions on monocytes/macrophages inhibiting their activation

The fifth-generation fluoroquinolone with in vitro coverage of community-acquired bacterial pneumonia (CABP) pathogens, atypical respiratory pathogens, multidrug-resistant Streptococcus pneumoniae and methicillin-resistant Staphylococcus aureus

Novel USP28 inhibitor

Novel selective USP7 inhibitor (USP7 IC50 9 μM; USP8 >50μM)

Novel USP28 inhibitor

First-in-class allosteric inhibitor of respiratory syncytial virus (RSV), blocking RNA elongation by the respiratory syncytial virus polymerase complex

Novel, highly potent p53-MDM2 inhibitor with an IC50 value of 0.08 nmol/L, displaying excellent oral efficacy in the human SJSA1-based xenograft model.

Novel USP28 inhibitor

Novel USP30 inhibitor

Monoselective agonist of the S1P(1) receptor

Novel anticancer agent, exhibiting potential cytotoxicity and inhibiting autophagy in hepatocellular carcinoma (HCC) cells

Novel inhibitor of autophagy, promoting metabolic stress within the tumour microenvironment and potentiating the effect of cytostatics in combination therapy

Unique signaling molecule used in quorum sensing

Novel autophagy inhibitor, targeting mitochondrial complex I directly, leading to the potent inhibition of mitochondrial respiration as well as autophagy

Novel DNA damage inducer during G0/G1, S, and G2 cell cycle phases via a mechanism unique from other DNA damaging agents

Novel potent ATP-competitive inhibitor of Aurora A/B/C (5.6/18.4/24.6 nM)

Novel small 4 integrin antagonist, preventing the development of experimental colitis in mice.

Potent inhibitor of HCV RdR

Novel inhibitor of AChE, suppressing Aβ aggregation, protecting Caenorhabditis elegans against Aβ- and 6-OHDA-induced neurotoxicities dose-dependently

Natural antibiotic

Novel AURKA inhibitor, reducing clonogenicity, arresting the cell cycle at the G2/M phase, and inducing caspase-mediated apoptotic cell death in HCT116 human colon cancer cells

Potent inhibitor of HCV RdR

Novel inhibitor of JAK/STAT signaling, inhibiting both constitutive and interleukin-6-induced STAT3 phosphorylation, selectively affecting cell viability only of cancer cells harboring aberrant JAK/STAT signaling

Novel selective Autotaxin (ATX) inhibitor

Novel Potent Autotaxin (ATX) Ligand

Novel potent, highly selective, orally bioavailable CDK9/P-TEFb inhibitor